This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Taltz
  • /
  • A Study of Ixekizumab (LY2439821) in TNF Inhibitor...
Clinical trial

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (COAST-W)

Read time: 2 mins
Last updated:1st Apr 2016
Identifier: NCT02696798

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Study Start Date: April 2016
Actual Primary Completion Date: May 18, 2018
Estimated Study Completion Date: January 31, 2019

Arm:
- Experimental:
Q2W Ixekizumab
- Experimental: Q4W Ixekizumab
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2018-07-04
Study type(s) Interventional
Expected enrolment 300
Study start date 2016-04-01
Estimated primary completion date 2018-05-18

View full details